IMUNON reports 14.7-month survival advantage for IMNN-001 in ovarian cancer trial
AI Summary- IMUNON presented OVATION 2 survival results and OVATION 3 operational updates for IMNN-001.
- 45.1 months was median overall survival with IMNN-001 versus 30.4 months for standard care.
- OVATION 3 targets enrollment completion in the first quarter of 2029.